Identifying continence options after stroke (ICONS): A cluster randomised controlled feasibility trial by Thomas LH et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Thomas LH, Watkins CL, Sutton CJ, Forshaw D, Leathley MJ, French B,  
Burton CR, Cheater F, Roe B, Britt D, Booth J, McColl E, Leathley M, Carter B, Booth J, 
Burton C, Rodgers H, Brittain K, Walker A, Barrett J, Whiteley G, Brand P, Griffiths M, 
Helvin P, James B, Pearl G, Whitewood J, Vella J,  
Childs R, Crosby S, Hall S, Lewin A, Royle L, Scott C, Wright J.  
Identifying continence options after stroke (ICONS): A cluster randomised controlled 
feasibility trial.  
Trials 2014, 15: 509. 
Copyright: 
© Thomas et al.; licensee BioMed Central. 2014 
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed 
under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original work is properly credited. The Creative Commons 
Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the 
data made available in this article, unless otherwise stated. 
DOI link to article: 
https://doi.org/10.1186/1745-6215-15-509  
Date deposited:   
13/11/2017 
TRIALS
Thomas et al. Trials 2014, 15:509
http://www.trialsjournal.com/content/15/1/509RESEARCH Open AccessIdentifying continence options after stroke (ICONS):
a cluster randomised controlled feasibility trial
Lois H Thomas1*, Caroline L Watkins1, Christopher J Sutton1, Denise Forshaw1, Michael J Leathley1,
Beverley French1, Christopher R Burton2, Francine Cheater3, Brenda Roe4, David Britt5, Joanne Booth6,
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Background: Urinary incontinence (UI) affects half of patients hospitalised after stroke and is often poorly managed.
Cochrane systematic reviews have shown some positive impact of conservative interventions (such as bladder training)
in reducing UI, but their effectiveness has not been demonstrated with stroke patients.
Methods: We conducted a cluster randomised controlled feasibility trial of a systematic voiding programme (SVP)
for the management of UI after stroke. Stroke services were randomised to receive SVP (n = 4), SVP plus
supported implementation (SVP+, n = 4), or usual care (UC, n = 4).
Feasibility outcomes were participant recruitment and retention. The main effectiveness outcome was presence or
absence of UI at six and 12 weeks post-stroke. Additional effectiveness outcomes included were the effect of
the intervention on different types of UI, continence status at discharge, UI severity, functional ability, quality
of life, and death.
Results: It was possible to recruit patients (413; 164 SVP, 125 SVP+, and 124 UC) and participant retention
was acceptable (85% and 88% at six and 12 weeks, respectively). There was no suggestion of a beneficial
effect on the main outcome at six (SVP versus UC: odds ratio (OR) 0.94, 95% CI: 0.46 to 1.94; SVP+ versus UC:
OR: 0.62, 95% CI: 0.28 to 1.37) or 12 weeks (SVP versus UC: OR: 1.02, 95% CI: 0.54 to 1.93; SVP+ versus UC:
OR: 1.06, 95% CI: 0.54 to 2.09).
No secondary outcomes showed a strong suggestion of clinically meaningful improvement in SVP and/or SVP+
arms relative to UC at six or 12 weeks. However, at 12 weeks both intervention arms had higher estimated odds of
continence than UC for patients with urge incontinence.
Conclusions: The trial has met feasibility outcomes of participant recruitment and retention. It was not powered to
demonstrate effectiveness, but there is some evidence of a potential reduction in the odds of specific types of
incontinence. A full trial should now be considered.
Trial registration: ISRCTN Registry, ISRCTN08609907, date of registration: 7 July 2010.
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Urinary incontinence (UI) following stroke is common, af-
fecting around half of stroke survivors in the acute phase
[1,2]. As many as 43.5% and 38% remain incontinent at
three months and one year, respectively [3]. In longer term
stroke survivors (on average nine years post-stroke), UI
prevalence has been reported as 17% [4].
Despite availability of clinical guidelines for the man-
agement of UI after stroke [5], national audit data [6]
suggest incontinence is often poorly managed. In the latest
National Sentinel Stroke Audit [6] only 63% of incontinent
patients had a plan for continence management, an in-
crease of just 5% since 2004. Improvements in continence
have not kept pace with those in other aspects of stroke
care, for example establishing a safe swallow, where the
proportion assessed has increased from 63 to 83% over the
same period. Research also demonstrates a lack of imple-
mentation of continence management practices, even by
specialist teams working in recognised stroke units [7,8].
A lack of guideline implementation may reflect the
limited evidence to support clinical guidelines; evidence
to underpin the management of UI after stroke is poor,
with no robust studies evaluating interventions in sec-
ondary care [9]. We have developed an intervention that
focusses on conservative strategies shown to have some
effect on UI in Cochrane systematic reviews [10-12], but
not with stroke patients. It comprises a systematic void-
ing programme (SVP) including a combined package of
bladder training and pelvic floor muscle training, or
prompted voiding, together with assessment and review.
In this paper, we report findings from a cluster rando-
mised controlled feasibility trial that aimed to explore
rates of recruitment and retention of participants, and to
provide preliminary evidence of the clinical effectiveness
of the intervention. The trial protocol has been pub-
lished previously [13].
Methods
Study setting and design
The study setting was 12 National Health Service (NHS)
stroke services in England and Wales. For the purpose of
the trial, a stroke service comprised both acute and rehabili-
tation stroke units. Stroke units were defined according to
the definition provided by the Royal College of Physicians
of London for the National Sentinel Stroke Audit [14]. We
used an open, cluster randomised controlled trial design
with non-blinded outcome assessment; all outcomes (with
the exception of death) were self-reported.
Inclusion criteria
Stroke services:
1. specialist acute and rehabilitation services (either
separate or combined units).Patients:
1. Aged 18 years or over with a diagnosis of stroke
based on the World Health Organisation (WHO)
criteria [15],
2. UI as defined by the International Continence
Society [16] as ‘involuntary loss of urine’ and
classified as stress UI (any response other than
‘never’ to the Leicester Urinary Symptom
questionnaire [17] (LUSQ) question ‘Do you ever
leak when you do any of the following?’), urge UI
(the response ‘most of the time’, ‘sometimes’ or
‘occasionally’ to the LUSQ question ‘When you get
the urge to pass urine, does any leak before you get
to the toilet?’), mixed UI (both stress and urge UI)
or ‘functional’ UI, defined as mobility or balance
restrictions stopping patients reaching the toilet on
time or presence of indwelling catheter in the acute
phase of the stroke,
3. Conscious (defined as either ‘alert’ or ‘drowsy’ on
the ‘Clinical Status on Admission’ item of the
European Stroke Database),
4. Medically stable as judged by the clinical team.Exclusion criteria
Stroke services:
1. No access to appropriate excess treatment costs (the
difference between the cost to the NHS of providing
the new treatment and the cost of standard
treatment [18]),
2. Inadequate throughput (defined as less than 150
admissions with stroke per annum),
3. Hub and spoke service model (centralised hyper-acute
care followed by rehabilitation provision in several
local stroke units) as resources did not allow for SVP
implementation in several rehabilitation units in one
stroke service.
Patients:
1. Pre-existing long-term catheter,
2. Routine intermittent self-catheterisation prior to
stroke,
3. Patients unable to consent for themselves, and for
whom a consultee did not agree that the patient
would wish to be included.Participant recruitment
As the trial was randomised by cluster, informed consent
was sought from all participants for collection of process
and outcome data only. All eligible patients in stroke
services randomised to intervention groups were treated
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sented to data collection.
All patients admitted to participating stroke units were
screened by research nurses within 72 hours of admis-
sion using a screening form in line with the inclusion
criteria. Nursing staff asked each eligible patient whether
their name could be given to the research team. If the
patient agreed, a member of the research team visited the
patient, explained the project, answered any questions,
and provided a participant information leaflet. Patients
were given at least 24 hours to consider participation and
were visited by a member of the research team after this
period. Patients choosing to participate signed the consent
form at this stage.
For patients unable to consent for themselves, a per-
son able to advise on the presumed wishes of the patient
was approached to act in the role of consultee. This is in
line with the recommendations of the Mental Capacity Act
(2005; United Kingdom) and in line with the expressed
wish of the study Patient, Public, and Carer Involvement
Groups that everyone who was eligible should have the op-
portunity to participate.
The trial was approved by the Bradford Research
Ethics Committee (reference number: 10/H1302/60), and
by research and development departments in the follow-
ing Trusts and Health Boards: Betsi Cadwaladr University
Health Board (no reference number); Blackpool, Fylde and
Wyre Hospitals NHS Foundation Trust (reference num-
ber: RD0563); Cambridge Universities Hospital NHS
Foundation Trust (reference number: AO92132); Cardiff
and Vale University Health Board (reference number: 10/
CMC/49); Cwm Taf Health Board (reference number:
CT/118/10); East Lancashire Hospitals NHS Trust (refer-
ence number: 2010/030); Lancashire Teaching Hospitals
NHS Foundation Trust (reference number: 1298); North
Cumbria University Hospitals NHS Trust (reference num-
ber: 124/10); and University Hospitals of Morecambe Bay
NHS Trust (reference number: SFRC 471).
Sample size and randomisation
The sample size was chosen pragmatically, rather than
on the basis of a formal power calculation. Our aim was
to balance practicalities and the need for reasonable pre-
cision in the estimation of effects to inform the sample
size calculation for a full trial.
In order to ensure comparability of trial arms with re-
spect to type of unit, quality of care, and throughput,
stroke services were placed into four strata of equal size.
These were based, in order of priority, on (1) whether
they had separate or combined acute and rehabilitation
units at the time (in one site, separate units had com-
bined by the start of recruitment); (2) their average per-
formance on the ‘nine key indicators of stroke care’ in
the National Sentinel Stroke Audit Phase II (clinicalaudit) [6]; (3) the number of stroke patients admitted
per year. Services were randomly allocated to usual care
(n = 4), intervention (n = 4), and supported implementa-
tion (n = 4) arms by the Newcastle Clinical Trials Unit.
After allocating stroke services to the strata, the ran-
domisation schedule was generated using block random-
isation (block length of three) to allocate one site to each
arm within every stratum. The software package STATA
(version nine, StataCorp LP, College Station, Texas, USA)
was used.
Trial arms
Usual care
In services randomised to usual care, participants re-
ceived usual continence care which could comprise of:
checking for urinary tract infection; checking for over-
flow incontinence; containment using a variety of prod-
ucts (for example absorbent pads) with regular changes;
and some form of toileting schedule.
Intervention
In addition to usual care, patients in services randomised
to the intervention arm received an SVP comprising as-
sessment, conservative interventions, and review. The
assessment phase comprised a three-day bladder diary
and a comprehensive continence assessment based on a
set of evidence-based criteria [19]. Unit staff were en-
couraged not to use indwelling urethral catheters unless
there was a valid reason. Patients who were cognitively
able received bladder training and those with cognitive
impairment received prompted voiding. Bladder training
included three main components: (1) focused education
for patients and carers (including information on the anat-
omy and physiology of the lower urinary tract, the ration-
ale behind the programme, and strategies to suppress
the urge to void, for example distraction and relaxation
[20,21]); (2) individualised voiding regimens designed to re-
store normal voiding patterns by progressively lengthening
the time interval between voids, based on assessment of
participants’ normal voiding patterns and self-monitoring;
(3) patient-held voiding diary, a cognitive intervention de-
signed to promote self-awareness of voiding habits [22,23].
While the intention was to combine pelvic floor muscle
training with bladder training, implementing pelvic floor
muscle training required the support of the physiotherapy
team in terms of assessing whether participants were able
to exercise their pelvic floor muscles. The physiotherapy
teams were reluctant to participate in all units and it was
therefore not possible to implement this part of the SVP.
For those patients with cognitive impairments, the
programme consisted of elements traditionally classified
as prompted voiding. Unlike bladder training, prompted
voiding is not designed to affect bladder function, but
to avoid or minimise episodes of incontinence [24].
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schedules (for example, every two hours during waking
hours), asked if they were dry or wet, and prompted to
use the toilet [25]. Verbal praise was offered for correct
reporting of dryness, wetness, and successful toileting.
Supported implementation
Services randomised to the supported implementation
arm of the trial introduced the SVP using an implementa-
tion strategy, facilitation, to assist the process of embedding
into practice. Facilitation involves supporting and enabling
people to change their practices [26,27]. It has been used
successfully in secondary care settings [26,27] and is cur-
rently the focus of an international trial of ‘technical’ and
‘enabling’ facilitation in a nursing home context [28]. Facili-
tation involves guiding the group towards accomplishing a
goal, helping members identify obstacles that may impede
progress and enabling them to identify strategies to over-
come them [29]. While there was a focus on goal attain-
ment (defined as the normalisation of the SVP), our
approach to facilitation primarily focused on ‘enabling’ ra-
ther than ‘doing for’ others [30], with an emphasis on de-
veloping and empowering both individuals and teams.
We used both internal and external facilitation. The
external facilitators were a senior research fellow in
evidence-based practice and a consultant nurse in stroke
care; both had expertise in leadership and change man-
agement. Each had responsibility for two sites. Their role
was to help internal facilitators understand how to bring
about change in health professional practice in order to
embed the SVP. They also supported internal facilitators by
way of encouragement, mentoring, and providing feedback.
We employed the expertise of at least one specialist practi-
tioner (staff members who were experts in the field of
stroke and incontinence) per stroke service allocated to this
arm to serve as internal facilitators. This role was typically
adopted by stroke unit nursing managers and involved
helping teams work together, providing the necessary infor-
mation and training, maintaining motivation, and giving
feedback and practical help when needed.
Allocation concealment
Within each stratum, stroke services were not informed of
their intervention allocation until all stroke services within
that stratum were recruited to take part in the trial. How-
ever, when two sites required substitution (one site with-
drew due to the pressure of other changes within the stroke
service and another site was found to have a throughput of
only 120 stroke patients per annum) the rest of the stratum
were already aware of their allocation.
Blinding
Once all stroke services within a stratum were recruited,
each was made aware of their allocation, as were staffidentifying and recruiting trial participants from within that
service. Outcome assessment was by self-reported mea-
sures, with data collection supported by research nurses for
participants who were still inpatients at six and 12 weeks
post-stroke, therefore blinded outcome assessment was not
possible. The trial statistician was not blinded during the
analysis, although the statistical analysis plan was finalised
prior to any outcome data being available.
Baseline data
Patient characteristics recorded at baseline included: age*;
sex; ethnicity; consciousness level on admission (defined
as either ‘alert’ or ‘drowsy’ on the ‘Clinical Status on
Admission’ item of the European Stroke Database); side
of body affected by stroke; type of stroke; stroke sub-type
(Oxfordshire Community Stroke Project (OCSP) classifi-
cation [31]); day seven Barthel Index [32]; pre-stroke
Modified Rankin Scale (mRS [33])*; pre-stroke living cir-
cumstances*; LUSQ (pre- and post-stroke [17]); type of UI
(urge UI, stress UI, mixed UI, ‘functional’ UI, or unclear);
cognitive ability (six-item Cognitive Impairment Test
[34]); verbal sub-section of the Glasgow Coma Scale [35]*;
ability to lift both arms off the bed*; ability to walk inde-
pendently*; International Consultation on Incontinence
Questionnaire (ICIQ-UI Short Form [36]); Incontinence
Severity Index (ISI [37]); and the EuroQol (EQ-5D-3 L [38]).
The six factors highlighted with a * above form the
Edinburgh stroke case-mix adjuster [39] and were col-
lected to enhance patient-level prognostic adjustment of
the statistical modelling of outcomes.
Outcome data
Outcome data were collected at six and 12 weeks post-
stroke via postal questionnaires or questionnaire com-
pletion supported by research nurses if participants were
still inpatients at either time point. A reminder, with an
additional copy of the questionnaire, was sent if postal
questionnaires were not received 14 days after sending
the original. If no response was received, participants
were telephoned and data collected either over the tele-
phone or in an arranged visit where the participant pre-
ferred. Those participants recruited to the trial after one
of the scheduled outcome assessments were not sub-
jected to outcome data collection for that time point.
Main outcome
The main effectiveness outcome was participant incontin-
ence (presence or absence) at six weeks as measured by
the ICIQ-UI Short Form. Absence of incontinence was
defined as the response ‘never’ to question three, ‘How
often do you leak urine?’. Presence of incontinence was
defined as any other response to question three (ranging
from ‘about once a week or less often’ to ‘all the time’).
This outcome was also measured at 12 weeks post-stroke.
Thomas et al. Trials 2014, 15:509 Page 5 of 15
http://www.trialsjournal.com/content/15/1/509Additional outcomes
Additional effectiveness outcomes measured at six and 12
weeks post-stroke were: quality of life measured using the
Incontinence Quality of Life Instrument (IQoL [40,41])
and the EQ-5D-3 L [38]; frequency and severity of incon-
tinence ascertained using the ISI; urinary symptoms mea-
sured using the LUSQ, including presence of urge and
stress incontinence as defined by Shaw et al. [17] respect-
ively as the response ‘most of the time’, ‘sometimes’ or ‘oc-
casionally’ to the LUSQ question ‘When you get the urge
to pass urine, does any leak before you get to the toilet?’,
and any response other than ‘never’ to the LUSQ question
‘Do you ever leak when you do any of the following?’; ac-
tivities of daily living (ADLs) measured using the Barthel
Index; and death.
A further exploratory effectiveness outcome, contin-
ence at discharge, was added to those reported in the
protocol. The purpose of this was to capture outcome at
the point where participants’ exposure to the interven-
tion ended; it was measured as described above under
the Main outcome section.
Statistical analyses
The primary analysis was performed on the basis of the
intention-to-treat principle. Outcome data were collected
from all consented patients whenever possible, regardless
of their level of subsequent engagement with the allocated
intervention programme. For the six-week outcome time
point, outcome data received no later than 10 weeks post-
stroke were included in the primary analysis; for the 12-
week outcome time point, all data received were included
with no restriction on when questionnaires were received.
To account for cluster randomisation we used mixed-
effects modelling for continuous, ordinal, and dichotomous
outcomes to compare the two groups. Baseline measures of
the outcome variables (where appropriate), stroke sub-type,
and the other prognostic patient-level information (via the
Edinburgh case-mix adjuster) were included as individual-
level covariates in the models for outcome data.
Missing outcome data were imputed according to the
particular outcome. For the primary analysis, dichotom-
ous and ordinal outcomes for those who withdrew, died,
or were otherwise lost to follow-up were imputed using
a worst-case scenario (for example, for the primary out-
come variable, all those for whom incontinence status
was not recorded at the respective time points post-stroke
were assumed to be incontinent). For continuous out-
comes (IQoL), the primary analysis used a non-parametric
multiple imputation approach [42]. Missing baseline
data were not imputed. Sensitivity analysis included per-
protocol analysis, using varying definitions of ‘receipt of
sufficient intervention’ and excluding patients with pre-
stroke incontinence, or those catheterised for the entirety
of their hospitalisation.Results
A total of 12 sites commenced recruitment between
January 2011 and January 2012. No site dropped out after
recruitment began, each recruiting participants either for
at least their planned duration of nine or 12 months or
until recruitment ceased at all sites on 31 July 2012. Site
recruitment periods ranged from seven to 16 months.
A total of 413 patients were recruited into the trial;
124 usual care, 164 intervention and 125 supported im-
plementation (Additional file 1). A total of 6,060 patients
were screened for eligibility; of these, 2,675 (44%) had
not had a confirmed stroke. The number of non-stroke
patients screened was highest in the intervention (1,515
out of 3,078, 49%) and supported implementation (981
out of 1,999, 49%) arms and lowest in usual care (179 out
of 983, 18%). There was a large variation across sites,
with non-stroke patients screened ranging from 2 (1%) to
448 (79%).
The proportion of stroke patients eligible for recruit-
ment was similar across trial arms (usual care: 155 out
of 804, 19%; intervention: 259 out of 1,563, 17%; and
supported implementation: 176 out of 1,018, 17%). Of
these, 80% (124 out of 155) were recruited into usual
care, 63% (164 out of 259) to intervention and 71% (125
out of 176) to supported implementation. The propor-
tion of eligible patients recruited ranged from 50 to 98%
across sites.
Baseline data were collected for all patients. The over-
all response rate at six weeks was 85% (306 out of 362),
excluding 34 patients recruited at more than six weeks
post-stroke and 17 who had died (usual care: 96 out of
114, 84%; intervention: 122 out of 139, 88%; supported
implementation: 88 out of 109, 81%). At 12 weeks, the
overall response rate was 88% (330 out of 374), exclud-
ing one patient recruited at 12 weeks and 38 who had
died (usual care: 98 out of 112, 88%; intervention: 132
out of 148, 89%; supported implementation: 100 out of
114, 88%).
Patient characteristics at baseline are shown in Table 1.
Median age was 79 years (interquartile range (IQR): 70.5
to 85) and was similar between arms. Overall, nearly half
were male (189, 46%); with slightly more males in the
intervention (86, 52%) arm compared with the usual care
(51, 41%) and supported implementation (52, 42%) arms.
Median day seven Barthel Index was 4 (IQR: 2 to 7) and
similar across all arms. The number of patients with no
symptoms on the pre-stroke mRS (and therefore no pre-
stroke disability) was 139 (34%) overall; the proportion
was slightly higher in the usual care (52, 42%) arm com-
pared with intervention (54, 33%) and supported imple-
mentation (33, 27%) arms. The median probability of
survival free of dependency at six months (measured by
the Edinburgh case-mix adjuster [39]) overall was 0.02
(IQR: 0.01 to 0.08) and was similar across all arms.
Table 1 Patient characteristics at baseline (frequency (%) unless stated otherwise)
Measure All sites Usual care Intervention Supported implementation
n = 413 n = 124 n = 164 n = 125
Median (IQR) age 79 (70.5-85) 80 (72-86) 77 (68-83) 81 (74-85)
Male 189 46% 51 41% 86 52% 52 42%
Ethnicity:
White British 397 97% 123 99% 155 96% 119 95%
Other 14 3% 1 1% 7 4% 6 5%
Type of stroke:
Ischaemic 350 85% 101 81% 143 88% 106 85%
Haemorrhagic infarct 49 12% 17 14% 14 9% 18 15%
Primary intracerebral haemorrhage 12 3% 6 5% 6 4% 0 0%
Oxfordshire Community Stroke Project (OCSP) Classification:
TACS, total anterior circulation syndrome 185 46% 37 30% 80 51% 68 54%
PACS, partial anterior circulation syndrome 118 29% 54 44% 31 20% 33 26%
LACS, lacunar stroke 88 22% 28 23% 44 28% 16 13%
POCS, posterior circulation syndrome 14 3% 3 2% 3 2% 8 6%
Side of body affected by stroke:
Left side 207 50% 58 47% 86 53% 63 50%
Right side 176 43% 55 44% 69 43% 52 42%
Both sides 6 1% 2 2% 2 1% 2 2%
Neither side 21 5% 9 7% 4 2% 8 6%
Median (IQR) seven-day Barthel Index 4 (2-7) 5 (2-9) 3 (2-6.3) 5 (3-7.5)
Pre-stroke Modified Rankin Scale:
No symptoms 139 34% 52 42% 54 33% 33 27%
No significant disability 166 41% 39 31% 72 44% 55 45%
Slight disability 30 7% 4 3% 19 12% 7 6%
Moderate disability 54 13% 21 17% 10 6% 23 19%
Moderately severe disability 18 4% 7 6% 6 4% 5 4%
Severe disability 2 0% 1 1% 1 1% 0 0%
Pre-stroke living type:
House 324 79% 94 76% 134 84% 96 77%
Flat 47 12% 21 17% 11 7% 15 12%
Sheltered housing 20 5% 4 3% 8 5% 8 6%
Residential home 15 4% 5 4% 4 3% 6 5%
Nursing home 1 0% 0 0% 1 1% 0 0%
Other 1 0% 0 0% 1 1% 0 0%
Pre-stroke living circumstances:
Alone 162 40% 51 41% 64 40% 47 38%
With partner 194 47% 57 46% 77 48% 60 48%
With other family 37 9% 11 9% 14 9% 12 10%
With other 16 4% 5 4% 5 3% 6 5%
Speech:
None 47 11% 10 8% 22 14% 15 12%
Incomprehensible 63 15% 19 15% 22 14% 22 18%
Inappropriate 72 18% 25 20% 32 20% 15 12%
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Table 1 Patient characteristics at baseline (frequency (%) unless stated otherwise) (Continued)
Cognitive ability:
Confused 83 20% 26 21% 22 14% 35 28%
Orientated 146 36% 44 35% 64 40% 38 30%
Median (IQR) Edinburgh case-mix probability of survival
free of dependency at six months
0.02 (0.01-0.08) 0.02 (0.01-0.05) 0.02 (0.01-0.11) 0.02 (0.01-0.08)
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strokes (total anterior circulation or partial anterior cir-
culation syndrome; 303, 74%), although the proportion
of patients with partial anterior circulation syndrome was
higher in the usual care (54, 44%) arm compared with
intervention (31, 19%) and supported implementation (33,
26%) arms.
Main effectiveness outcome
Table 2 shows patient outcomes at six weeks post-
stroke. An odds ratio (OR) greater than 1 favours the
intervention (intervention or supported implementation
arms). Overall, only 66 (29%) patients reported being
continent, with another 76 (25%) reporting the presence
of an indwelling urethral catheter. There was no sugges-
tion of a beneficial effect on outcome of either interven-
tion relative to usual care, with adjusted OR estimates
for the dichotomised form of ICIQ question three of
0.94 (95% CI: 0.46 to 1.94) for the intervention arm and
0.62 (95% CI: 0.28 to 1.37) for the supported implemen-
tation arm, and for the original ordinal form of the ques-
tion, 0.83 (95% CI: 0.49 to 1.38) and 0.89 (95% CI: 0.52
to 1.51), respectively.
At 12 weeks, there was no evidence of better outcome
on the ICIQ in either intervention arm (Table 3); OR es-
timates for the dichotomised form of ICIQ question
three were 1.02 (95% CI: 0.54 to 1.93) for the interven-
tion arm and 1.06 (95% CI: 0.54 to 2.09) for the sup-
ported implementation arm and, for the original ordinal
form of the question, 0.97 (95% CI: 0.58 to 1.61) and
1.22 (95% CI: 0.72 to 2.08), respectively.
Other effectiveness outcomes
There was no suggestion of a clinically meaningful im-
provement in the intervention and/or supported imple-
mentation arms relative to usual care at six or 12 weeks
post-stroke for any of the other outcomes. At six weeks,
44% (100) of the non-catheterised respondents reported
severe incontinence on the ISI, with similar percentages
with severe incontinence in each trial arm (usual care:
35, 47%; intervention: 38, 45%; supported implementa-
tion: 27, 40%).
At 12 weeks, both intervention arms had a higher esti-
mated odds of continence than usual care with respect
to urge incontinence (intervention: OR: 1.58, 95% CI: 0.83
to 2.99, supported implementation: OR: 1.73, 95% CI: 0.88to 3.43). There was a greater estimated odds of continence
with respect to stress incontinence in the supported im-
plementation (OR: 1.82, 95% CI: 0.82 to 4.01) arm but not
the intervention (OR: 1.04, 95% CI: 0.45 to 1.82) arm,
compared with usual care.
There was a consistent pattern of worse estimated ef-
fects of the intervention on EQ-5D-3 L outcomes, but
only the confidence intervals for the effect of the inter-
vention arm (relative to usual care) on usual activity and
anxiety and depression at six weeks, and on self-care and
usual activities at 12 weeks, suggested ORs below one
(poorer quality of life).
Overall, 161 (39.7%) participants were continent at
discharge; 38 (31%) in usual care, 72 (44%) in the inter-
vention arm, and 51 (41%) in the supported implementa-
tion arm. Relative to usual care, the intervention arm
had an OR of 1.47 (95% CI: 0.81 to 2.67) of being dis-
charged continent, with supported implementation hav-
ing an OR of 1.54 (95% CI: 0.83 to 2.85). On combining
the two intervention arms, their participants had 1.50
(95% CI: 0.88 to 2.57) times the odds of continence at
discharge than usual care.
Sensitivity analysis
At both six and 12 weeks, findings were insensitive to
the exclusion of those catheterised throughout their hos-
pital stay (and also to the exclusion of those who were
never incontinent following the removal of a catheter).
However, at both time points, odds ratios reduced when
those with pre-stroke incontinence were excluded.
Discussion
Recruitment
The number of potential participants available for re-
cruitment was affected by the large proportion of people
admitted who did not have a stroke, which comprised
nearly half of those admitted to the intervention (1,515,
49%) and supported implementation (981, 49%) units. A
potential explanation may be hospital policies on bed
usage: two intervention units also admitted medical pa-
tients when there was a shortage of medical beds in the
hospital, while in two supported implementation units
only a proportion of beds were designated for patients
with stroke (18 out of 26 and 12 out of 28). In one unit,
two-weekly rotations of medical staff across geriatric
medicine meant a definitive diagnosis of stroke was often
Table 2 Patient outcomes at six weeks post-stroke
Trial arm
Usual
care (UC)
Intervention (I) Odds ratio (95% CI)
I versus UCe
Supported
implementation (SI)
Odds ratio 5% CI)
SI versus Ce
All sites Intracluster Correlation
Coefficient (ICC)c
Questionnaires returned 96 122 88 306
Catheterised (% of returned) 21 22% 37 30% 18 20% 76 25%
Potential respondents for incontinence measures
(% age of returned)
75 78% 85 70% 70 80% 230 75%
Primary outcome: presence or absence of incontinence
(ICIQ-UI Short-Form question three)
0.94 (0.46-1.94) 0.62 (0.28 .37) 0
Continenta 21 28% 29 34% 16 23% 66 29%
Incontinentb 54 72% 56 66% 54 77% 164 71%
ICIQ-UI Short Form (UC: 75; I: 83; SI: 70; All: 228)f 0.83 (0.49-1.38) 0.89 (0.52 .51) 0
Never 21 30% 29 41% 16 24% 66 31%
About once a week or less often 8 11% 7 10% 11 16% 26 12%
Two or three times per week 12 17% 10 14% 8 12% 30 14%
About once a day 9 13% 11 15% 12 18% 32 15%
Several times a day 25 35% 25 35% 22 32% 72 34%
All the time 0 0% 1 1% 1 1% 2 1%
Secondary outcomes
Incontinence Severity Index (ISI) score
(UC: 75; I: 84; SI: 68; All: 227)f
0.87 (0.48-1.57) 0.84 (0.46 .56) 0
Median (IQR) 4 0-8 4 0-8 4 1-8 4 (0-8)
None (0) 21 28% 29 35% 16 24% 66 29%
Slight (1-2) 6 8% 6 7% 7 10% 19 8%
Moderate (3-4) 13 17% 11 13% 18 26% 42 19%
Severe (6-8) 35 47% 38 45% 27 40% 100 44%
Leicester Urinary Symptom Questionnaire
Frequency of toilet visits during daytime
(UC: 71; I: 71; SI: 68; All: 210)f
0.43 (0.22-0.84) 0.60 (0.30 .22) 0.017
At least every 30 minutes 0 0% 0 0% 0 0% 0 0%
Every hour 0 0% 0 0% 0 0% 0 0%
Every 90 minutes 2 3% 2 3% 1 1% 5 2%
Every 2 hours 2 3% 2 3% 10 15% 14 7%
Less often than every 2 hours 67 94% 67 94% 57 84% 191 91%
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Table 2 Patient outcomes at six weeks post-stroke (Continued)
Types of incontinence
Urge incontinence present (UC: 75; I: 84; SI: 68; All: 227)f 52 70% 50 59% 1.35 (0.67-2.71) 48 71% 0.89 (0.41-1.91) 150 66% 0
Stress incontinence present (UC: 71; I: 78; SI: 57; All: 206)f 36 51% 32 41% 1.01 (0.42-2.43) 33 58% 0.82 (0.34-1.61) 101 49% 0
EQ-5D-3 L
Mobility (UC: 96; I: 114; SI: 88; All: 298)f 1.27 (0.69-2.34) 1.37 (0.74-2.53)
No problems 13 14% 10 9% 6 7% 29 10%
Some problems 51 53% 44 39% 48 55% 143 48%
Confined to bed 32 33% 60 53% 34 39% 126 42%
Self-care (UC: 96; I: 114; SI: 88; All: 298)f 0.61 (0.34-1.09) 0.75 (0.40-1.39) 0
No problems 13 14% 13 11% 13 15% 39 13%
Some problems 49 51% 47 41% 36 41% 132 44%
Unable to wash or dress 34 35% 54 47% 39 44% 127 43%
Usual activity (UC: 96; I: 114; SI: 88; All: 298)f 0.42 (0.22-0.81) 0.79 (0.41-1.51) 0
No problems 6 6% 5 4% 5 6% 16 5%
Some problems 44 46% 30 26% 34 39% 108 36%
Unable to perform 46 48% 79 69% 49 56% 174 58%
Pain or discomfort (UC: 95; I: 111; SI: 84; All: 290)f 0.66 (0.38-1.16) 0.63 (0.34-1.14) 0
None 62 65% 58 52% 52 62% 172 59%
Moderate 32 34% 48 43% 29 35% 109 38%
Extreme 1 1% 5 5% 3 4% 9 3%
Anxiety or depression (UC: 95; I: 107; SI: 83; All: 285)f 0.56 (0.33-0.95) 0.86 (0.49-1.51) 0
None 51 54% 47 44% 47 57% 145 51%
Moderate 42 44% 54 50% 33 40% 129 45%
Extreme 2 2% 6 6% 3 4% 11 4%
Mean (SD) incontinence Quality of lifed
(UC: 53; I: 43; SI: 38; All: 134)f
75 (56.7-90.9) 78.4 (37.5-89.8) −10.1 (−29.5-9.3) 74.4 (48.3-92.1) −10.1 (−28.6-8.3) 76 (51.7-91.2) 0.184
Median (IQR) Barthel Index
(UC: 96; I: 117; SI: 88; All: 301)f
8.5 (3-14) 7 (3-11) 0.68 (0.43-1.07) 7.5 (4-12) 0.70 (0.43-1.13) 8 (3-12) 0
Dead (UC: 118; I: 145; SI: 114; All: 377)f 4 3% 7 5% 1.01 (0.43-2.39) 6 5% 0.72 (0.31-1.71) 17 5% 0.0087
aDefined as never on the ICIQ-UI Short Form response question three.
bDefined as any non-missing response other than ‘never’ on the ICIQ-UI Short Form.
cAny ICC estimate <10−6 is presented as 0.
dExcluding participants recorded as continent or catheterised.
eORs based on imputed data; values >1 favour I or SI over UC.
fData available for UC, I, SI, and all sites.
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Table 3 Patient outcomes at 12 weeks post-stroke
Trial arm
Usual care (UC) Intervention (I) Odds ratio (OR)
(95% CI) I versus UCe
Supported
implementation
OR (9 CI)
SI vers UCe
All sites Intracluster Correlation
Coefficient (ICC)c
Questionnaires returned 98 132 100 330
Catheterised (% of returned) 18 18% 27 20% 13 13% 58 17%
Potential respondents for incontinence measures
(% age of returned)
80 82% 105 80% 86 86% 271 82%
Primary outcome: presence or absence of incontinence
(ICIQ-UI Short-Form question three)
Continenta 24 30% 43 41% 1.02 (0.54-1.93) 27 31% 1.06 (0. 2.09) 94 35% 0
Incontinentb 56 70% 62 59% 59 68% 177 65%
ICIQ-UI Short Form (UC: 80; I: 104; SI: 86; All: 270)f 0.97 (0.58-1.61) 1.22 (0. 2.08) 0
Never 24 30% 43 41% 27 31% 94 35%
About once a week or less often 12 15% 9 9% 10 12% 31 12%
Two or three times per week 12 15% 13 12% 11 13% 36 13%
About once a day 12 15% 6 6% 10 12% 28 10%
Several times a day 18 23% 25 24% 27 31% 70 26%
All the time 2 3% 8 8% 1 1% 11 4%
Secondary outcomes
Incontinence Severity Index (ISI) score
(UC: 80; I: 102; SI: 86; All: 268)f
0.86 (0.50-1.50) 0.92 (0. 1.64) 0
Median (IQR) 3 (0-6) 2.5 (0-8) 4 (0-8) 3 (0-8)
None (0) 24 30% 43 42% 28 33% 95 35%
Slight (1-2) 10 13% 8 8% 6 7% 24 9%
Moderate (3-4) 19 24% 12 12% 17 20% 48 18%
Severe (6-8) 27 34% 39 38% 35 41% 101 38%
Leicester Urinary Symptom Questionnaire
Frequency of toilet visits during daytime
(UC: 73; I: 88; SI: 71; All: 232)f
0.85 (0.47-1.54) 1.09 (0. 1.96) 0.0075
At least every 30 minutes 0 0% 0 0% 0 0% 0 0%
Every hour 0 0% 0 0% 1 1% 1 0%
Every 90 minutes 5 7% 2 2% 4 6% 11 5%
Every 2 hours 10 14% 11 13% 6 8% 27 12%
Less often than every 2 hours 58 79% 75 85% 60 85% 193 83%
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Table 3 Patient outcomes at 12 weeks post-stroke (Continued)
Type of incontinence
Urge incontinence present (UC: 79; I: 103; SI: 85; All: 267)f 53 67.1% 52 50.5% 1.58 (0.83-2.99) 49 57.6% 1.73 (0.88-3.43) 154 57.7% 0
Stress incontinence present (UC: 72; I: 83; SI: 72; All: 227)f 38 52.8% 29 34.9 1.04 (0.45-1.82) 31 43.1 1.82 (0.82-4.01) 98 43.2% 0
EQ-5D-3 L
Mobility (UC: 96; I: 129; SI: 92; All: 317)f 0.92 (0.52-1.62) 0.79 (0.44-1.41) 0
No problems 19 20% 16 12% 10 11% 45 14%
Some problems 53 55% 62 48% 57 62% 172 54%
Confined to bed 24 25% 51 40% 25 27% 100 32%
Self-care (UC: 97; I: 126; SI: 92; All: 315)f 0.45 (0.26-0.79) 0.65 (0.36-1.16) 0
No problems 25 26% 21 17% 18 20% 64 20%
Some problems 42 43% 47 37% 40 43% 129 41%
Unable to wash or dress 30 31% 58 46% 34 37% 122 39%
Usual activities (UC: 97; I: 126; SI: 91; All: 314)f 0.49 (0.27-0.90) 0.63 (0.34-1.17) 0
No problems 10 10% 9 7% 8 9% 27 9%
Some problems 43 44% 39 31% 32 35% 114 36%
Unable to perform 44 45% 78 62% 51 56% 173 55%
Pain or discomfort (UC: 95; I: 123; SI: 93; All: 311)f 0.73 (0.43-1.23) 0.88 (0.50-1.54) 0
None 55 58% 51 41% 50 54% 156 50%
Moderate 37 39% 58 47% 34 37% 129 41%
Extreme 3 3% 14 11% 9 10% 26 8%
Anxiety or depression (UC: 95; I: 122; SI: 92; All: 309)f 0.67 (0.39-1.13) 0.95 (0.54-1.67) 0
None 53 56% 47 39% 47 51% 147 48%
Moderate 37 39% 66 54% 37 40% 140 45%
Extreme 5 5% 9 7% 8 9% 22 7%
Mean (SD) Incontinence Quality of Lifed
(UC: 51; I: 47; SI: 35; All: 133)f
72.6 (58.3-83.0) 76.1 (42.5-94.3) −5.5 (−24.1-13.1) 67.1 (51.1-85.2) −1.9 (−21.2-17.4) 72.6 (52.9-87.5) 0.216
Median (IQR) Barthel Index (UC: 94; I: 128; SI: 95; All: 317)f 11 (4-16) 8 (4-13) 0.71 (0.46-1.11) 11 (6-15) 0.97 (0.61-1.54) 10 (4-15) 0
Dead (UC: 123; I: 159; SI: 122; All: 404)f 12 10% 16 10% 1.04 (0.56-1.92) 10 8% 1.15 (0.60-2.19) 38 9% 0
aDefined as never on the ICIQ-UI Short Form response question three.
bDefined as any non-missing response other than ‘never’ on the ICIQ-UI Short Form.
cAny ICC estimate <10−6 is presented as 0.
dExcluding participants recorded as continent or catheterised.
eORs based on imputed data; values >1 favour I or SI over UC.
fData available for UC, I, SI, and All Sites.
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ticipants without this leading to patients being discharged
without being approached. Other units may have had inef-
fective procedures for diagnosing confirmed cases in the
emergency department, and/or a lack of nurse specialist
and/or stroke-specific consultant physician roles.
Recruitment of patients to the usual care arm was af-
fected by two further factors: throughput of patients and
length of the recruitment period. No large hospital (over
600 admissions with stroke per annum) was randomised
to this arm. Furthermore, in two hospitals delays in
obtaining approvals meant recruitment started much
later than planned, but still had to be stopped at the end
of July 2012 to allow sufficient time for data analysis and
reporting.
The actual numbers of people admitted with a con-
firmed stroke at individual centres were up to 65% lower
per annum than initial figures provided by the Trusts or
Health Boards. This difference was particularly marked
in the two intervention arms, with overall proportions
33% and 34% lower than estimates provided by the units
in the intervention and supported implementation arms,
respectively, compared with just 4% lower in usual care.
The mismatch between reported and actual numbers of
stroke patients meant there were fewer than expected eli-
gible patients. These lower numbers need to be accounted
for in our future trial, and in stroke trials more generally.
The proportion of people admitted with stroke that
were eligible for the trial (19% in usual care, and 17% in
each of the implementation and supported implementa-
tion units) was half that expected based on prevalence
reported in previous studies [3,43]. Possible explanations
are a larger than expected proportion of patients who
were not deemed to be medically stable, continent by
the time they were classed as medically stable, or receiv-
ing end of life care.
Interpretation of the inclusion criterion ‘medically stable’
was variable across sites and contributed to delays in
recruiting patients who were six or more weeks post-
stroke (34 patients) and, in one case, 12 weeks post-
stroke. Patients tended to be recruited slightly earlier in
the usual care arm (mean of 15.6 days post-stroke com-
pared with 21.1 days in the intervention arm and 17.9 in
the supported implementation arm). Delays in recruit-
ment could explain the lower than expected number of
people with mild incontinence, which could have resolved
by the time people were deemed to be medically stable.
In intervention arms, delays also affected when patients
began the SVP, contrary to current guidance suggesting all
those who are incontinent two weeks after diagnosis should
be reviewed and a treatment plan developed [5].
A larger percentage had less severe strokes (partial anter-
ior circulation syndrome (PACS)) compared with patients
in the intervention arms (usual care: 44%, intervention:20%, and supported implementation: 26%). While levels of
functioning were similar across trial arms at baseline, the
greater proportion of patients with PACS may have con-
tributed to better prognosis, both in terms of general re-
covery and recovery of continence in this trial arm.
In order to minimise the likelihood of baseline imbal-
ances in the full trial, consideration should be given to
recruiting patients within 72 hours of admission to the
stroke unit. Revised strategies for identifying patients
with mild incontinence (for example, including a review
of continence within the assessment process on admis-
sion to the unit) are also required. In intervention units,
the assessment phase of the SVP can begin during this
time, with components requiring more active input from
patients (for example, bladder training) beginning when
patients are deemed by the multidisciplinary team to be
ready to start active rehabilitation.
Sensitivity analysis indicates that odds of continence
may be reduced when those with pre-stroke UI are ex-
cluded. This suggests those with pre-stroke incontinence
are at least as, or more likely to benefit from the inter-
vention than those continent pre-stroke; this group of
patients should therefore be included in the full trial.Participant retention
The proportion of participants for whom outcome data
were available at six (85%) and 12 (88%) weeks was accept-
able [44] as there was less than 20% attrition. This was a
particular achievement given the nature of the patient
population: the median Barthel Index score was eight at
six weeks and 10 at 12 weeks, indicating severe disability.Preliminary evidence of effectiveness
There was no suggestion of a beneficial effect of the SVP
(with or without supported implementation) on outcome at
six weeks post-stroke. However, almost 50% of intervention-
arm patients had received less than two weeks of their
allocated intervention by this time point, with around
25% having spent less than seven days on the programme.
Outcome findings were similar at 12 weeks post-stroke,
although both intervention arms had a higher estimated
odds of continence at discharge and an increase in the es-
timated odds of continence for patients with urge incon-
tinence than usual care; there was a similar increase in the
estimated odds of continence for stress incontinence in
the supported implementation arm.
While none of these differences were statistically signifi-
cant, they suggest participants in intervention units were
more likely to be continent at discharge, and also point to
a potential reduction in the odds of specific types of in-
continence, with evidence more consistent across the
arms for urge incontinence. This may be explained by our
inability to introduce pelvic floor muscle training, with the
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get stress incontinence.
Despite extensive liaison with therapy staff, no inter-
vention sites included pelvic floor muscle training as
part of a combined intervention with bladder training.
Lack of therapist involvement in identifying, assessing,
and managing UI after stroke is at odds with the key role
recommended by both evidence [45-47] and policy [48].
Delivering the intervention as intended (as a combined
intervention of bladder training and pelvic floor muscle
training) may have led to a greater improvement in par-
ticipant outcomes.
Delays in both recruiting patients and beginning the
SVP may have attenuated the estimate of preliminary ef-
fectiveness at six weeks, particularly given that outcome
time points were measured from date of stroke rather
than either date of recruitment or date of commence-
ment of the SVP. This feasibility trial has indicated that
measuring outcome at 12 weeks may provide a more ac-
curate reflection of preliminary effectiveness, as by this
time patients had been on the SVP for a mean of 28.12
(SD: 18.45) days in the intervention arm and 26.36 (SD:
23.33) days in the supported implementation arm. The
12-week time point will be used as the main outcome
time point in the full trial. This will be measured from
date of consent in order to reduce the time from stroke
to consent found in this feasibility trial.
As the majority of patients were discharged before the
12-week data collection point (usual care: 110, 88.7%;
intervention: 131, 79.7%; supported implementation: 94,
76.4%), measuring presence or absence of continence at
discharge was useful in assessing preliminary evidence of
effectiveness as it allowed assessment at the end of the
intervention period (the point where effectiveness was
most likely to be demonstrated). The extent to which
the SVP was continued either at home or in other care en-
vironments is unknown, but there is some evidence to
suggest patients’ continence status regressed following dis-
charge. Overall, two fifths of patients continent at dis-
charge were incontinent at 12 weeks (22 out of 54, 40.7%);
a smaller proportion of patients were incontinent in the
intervention arm (7, 29.2%) compared with usual care
(8, 57.1%) and supported implementation (7, 43.8%).
The SVP protocol recommended avoiding catheterisa-
tion (except for the management of urinary retention or
where fluid balance was critical) and reviewing and re-
moving catheters as soon as possible after stroke, in line
with current guidance [5]. Nearly half of the patients in
intervention arms were catheterised in the acute stage
(139 out of 289, 48.1%). While this is much higher than
the 20% reported in the 2010 National Sentinel Audit
[6], this percentage is of those recruited and cannot ne-
cessarily be extrapolated to all people admitted to the
stroke unit.Given the high rate of catheterisation found in this study,
more detailed guidance needs to be added to intervention
protocols in the future trial, particularly around avoiding
unnecessary catheterisation, conducting a ‘trial without
catheter’ as soon as possible, and reviewing catheterised
patients on a weekly basis.
As the SVP was delivered only in the stroke unit, it is
possible patients did not receive the programme long
enough to benefit, with intervention and supported im-
plementation arm patients spending an average of 28
days and 37 days receiving the intervention, respectively.
The duration in previous studies was typically more than
six weeks for bladder training [12], and between 20 days
and 32 weeks for prompted voiding [10]. Encouraging
staff to begin the SVP as soon as patients are able to
begin rehabilitation, and extending the SVP beyond dis-
charge from the stroke unit, should be considered in
order to maximise the possibility of a treatment effect.
Conclusions
This feasibility trial demonstrated that it was possible to
recruit and retain participants, although this took longer
than planned. There is some evidence of more favourable
continence outcomes in intervention arms at 12 weeks,
particularly in those participants with urge and (to a lesser
extent) stress incontinence, and patients in the interven-
tion arms were more likely to be continent at discharge.
In terms of participant recruitment, the inclusion criter-
ion ‘medically stable’ should be removed, and the recruit-
ment process should begin within 72 hours of admission
to the stroke unit to help minimise imbalances at baseline,
with progression onto the SVP once patients are judged
ready to begin rehabilitative activities.
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recruitment.
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